Pharmacokinetics of vatinoxan in male neutered cats anesthetized with isoflurane
| Autor: | Bruno H Pypendop, Hanna Ahokoivu, Juhana Honkavaara |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
040301 veterinary sciences Population 0403 veterinary science 03 medical and health sciences 0302 clinical medicine Pharmacokinetics 030202 anesthesiology medicine Animals Distribution (pharmacology) Anesthesia Dexmedetomidine Infusions Intravenous education education.field_of_study CATS Isoflurane General Veterinary Small volume business.industry 04 agricultural and veterinary sciences Anesthetics Inhalation Cats Mixed effects business Orchiectomy Quinolizines medicine.drug |
| Zdroj: | Veterinary Anaesthesia and Analgesia. 47:70-75 |
| ISSN: | 1467-2987 |
| DOI: | 10.1016/j.vaa.2019.10.004 |
| Popis: | Objective To characterize the pharmacokinetics of vatinoxan in isoflurane-anesthetized cats. Study design Prospective experimental study. Animals A group of six adult healthy male neutered cats. Methods Cats were anesthetized using isoflurane in oxygen. Venous catheters were placed to administer the drug and sample blood. Vatinoxan, 1 mg kg–1, was administered intravenously over 5 minutes. Blood was sampled before and at various times during and up to 8 hours after vatinoxan administration. Plasma vatinoxan concentration was measured using liquid chromatography/tandem mass spectrometry. Compartment models were fitted to the time–concentration data using population methods and nonlinear mixed effect modeling. Results A three-compartment model best fitted the data. Typical value (% interindividual variability) for the three volumes (mL kg–1), the metabolic clearance and two distribution clearances (mL minute–1 kg–1) were 34 (55), 151 (35), 306 (18), 2.3 (34), 42.6 (25) and 5.6 (0), respectively. Hypotension increased the second distribution clearance to 10.6. Conclusion and clinical relevance The pharmacokinetics of vatinoxan in anesthetized cats were characterized by a small volume of distribution and a low clearance. An intravenous bolus of 100 μg kg–1 of vatinoxan followed by constant rate infusions of 55 μg kg–1 minute–1 for 20 minutes, then 22 μg kg–1 minute–1 for 60 minutes and finally 10 μg kg–1 minute–1 for the remainder of the infusion time is expected to maintain the plasma concentration within 90%–110% of the plasma vatinoxan concentration previously shown to attenuate the cardiovascular effects of dexmedetomidine (25 μg kg–1) in conscious cats. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|